Toll Free: 1-888-928-9744
Toll Free: 1-888-928-9744
Published: May, 2017 | Pages:
148 | Publisher: Global Markets Direct
Industry: Pharmaceuticals & Healthcare | Report Format: Electronic (PDF)
Irritable Bowel Syndrome - Pipeline Review, H1 2017 Summary Global Markets Direct's latest Pharmaceutical and Healthcare disease pipeline guide Irritable Bowel Syndrome - Pipeline Review, H1 2017, provides an overview of the Irritable Bowel Syndrome (Gastrointestinal) pipeline landscape. Inflammatory Bowel Diseases (IBD) is a broad term that describes conditions with chronic or recurring immune response and inflammation of the gastrointestinal tract. Signs and symptoms include abdominal cramps and pain, diarrhea that may be bloody, weight loss, loss of appetite and fever. The predisposing factors include age, family history, smoking and some pain killers. Treatment includes corticosteroids, immune suppressors, antibiotics and pain relievers. Report Highlights Global Markets Direct's Pharmaceutical and Healthcare latest pipeline guide Irritable Bowel Syndrome - Pipeline Review, H1 2017, provides comprehensive information on the therapeutics under development for Irritable Bowel Syndrome (Gastrointestinal), complete with analysis by stage of development, drug target, mechanism of action (MoA), route of administration (RoA) and molecule type. The guide covers the descriptive pharmacological action of the therapeutics, its complete research and development history and latest news and press releases. The Irritable Bowel Syndrome (Gastrointestinal) pipeline guide also reviews of key players involved in therapeutic development for Irritable Bowel Syndrome and features dormant and discontinued projects. The guide covers therapeutics under Development by Companies /Universities /Institutes, the molecules developed by Companies in Pre-Registration, Phase III, Phase II, Phase I, Preclinical and Discovery stages are 2, 3, 12, 7, 11 and 2 respectively. Similarly, the Universities portfolio in Preclinical stages comprises 1 molecules, respectively. Irritable Bowel Syndrome (Gastrointestinal) pipeline guide helps in identifying and tracking emerging players in the market and their portfolios, enhances decision making capabilities and helps to create effective counter strategies to gain competitive advantage. The guide is built using data and information sourced from Global Markets Direct's proprietary databases, company/university websites, clinical trial registries, conferences, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources. Additionally, various dynamic tracking processes ensure that the most recent developments are captured on a real time basis. Note: Certain content / sections in the pipeline guide may be removed or altered based on the availability and relevance of data. Scope - The pipeline guide provides a snapshot of the global therapeutic landscape of Irritable Bowel Syndrome (Gastrointestinal). - The pipeline guide reviews pipeline therapeutics for Irritable Bowel Syndrome (Gastrointestinal) by companies and universities/research institutes based on information derived from company and industry-specific sources. - The pipeline guide covers pipeline products based on several stages of development ranging from pre-registration till discovery and undisclosed stages. - The pipeline guide features descriptive drug profiles for the pipeline products which comprise, product description, descriptive licensing and collaboration details, R&D brief, MoA & other developmental activities. - The pipeline guide reviews key companies involved in Irritable Bowel Syndrome (Gastrointestinal) therapeutics and enlists all their major and minor projects. - The pipeline guide evaluates Irritable Bowel Syndrome (Gastrointestinal) therapeutics based on mechanism of action (MoA), drug target, route of administration (RoA) and molecule type. - The pipeline guide encapsulates all the dormant and discontinued pipeline projects. - The pipeline guide reviews latest news related to pipeline therapeutics for Irritable Bowel Syndrome (Gastrointestinal) Reasons To Buy - Procure strategically important competitor information, analysis, and insights to formulate effective R&D strategies. - Recognize emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage. - Find and recognize significant and varied types of therapeutics under development for Irritable Bowel Syndrome (Gastrointestinal). - Classify potential new clients or partners in the target demographic. - Develop tactical initiatives by understanding the focus areas of leading companies. - Plan mergers and acquisitions meritoriously by identifying key players and it's most promising pipeline therapeutics. - Formulate corrective measures for pipeline projects by understanding Irritable Bowel Syndrome (Gastrointestinal) pipeline depth and focus of Indication therapeutics. - Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope. - Adjust the therapeutic portfolio by recognizing discontinued projects and understand from the know-how what drove them from pipeline.
Table of Contents
Table of Contents 2 List of Tables 5 List of Figures 6 Introduction 7 Global Markets Direct Report Coverage 7 Irritable Bowel Syndrome - Overview 8 Irritable Bowel Syndrome - Therapeutics Development 9 Pipeline Overview 9 Pipeline by Companies 10 Pipeline by Universities/Institutes 13 Products under Development by Companies 14 Products under Development by Universities/Institutes 16 Irritable Bowel Syndrome - Therapeutics Assessment 17 Assessment by Target 17 Assessment by Mechanism of Action 20 Assessment by Route of Administration 23 Assessment by Molecule Type 25 Irritable Bowel Syndrome - Companies Involved in Therapeutics Development 27 4D Pharma PLC 27 A. Menarini Industrie Farmaceutiche Riunite Srl 27 Alfa Wassermann SpA 28 Allergan Plc 28 Ardelyx Inc 29 Astellas Pharma Inc 29 CJ HealthCare Corp 30 ConSynance Therapeutics Inc 30 Cosmo Pharmaceuticals NV 31 Dong-A ST Co., Ltd. 31 Eisai Co Ltd 32 Enterome Bioscience SA 32 GlaxoSmithKline Plc 33 Innovative Med Concepts LLC 33 Ironwood Pharmaceuticals Inc 34 Kissei Pharmaceutical Co Ltd 35 Lexicon Pharmaceuticals Inc 35 Napo Pharmaceuticals Inc 36 Pfizer Inc 36 RaQualia Pharma Inc 37 RedHill Biopharma Ltd 37 SK Biopharmaceuticals Co Ltd 38 Sumitomo Dainippon Pharma Co Ltd 38 Synergy Pharmaceuticals Inc 39 Synthetic Biologics Inc 39 Vitality Biopharma Inc 40 Irritable Bowel Syndrome - Drug Profiles 41 (celecoxib + famciclovir) - Drug Profile 41 ASP-7147 - Drug Profile 43 bedoradrine sulfate - Drug Profile 44 Biologic for Irritable Bowel Syndrome with Constipation - Drug Profile 47 Biologic for Irritable Bowel Syndrome with Diarrhea - Drug Profile 48 Blautix - Drug Profile 49 Canchew Plus - Drug Profile 51 CJ-14199 - Drug Profile 52 crofelemer DR - Drug Profile 53 CSTI-300 - Drug Profile 57 DA-6886 - Drug Profile 58 Drugs for Irritable Bowel Syndrome with Diarrhea - Drug Profile 59 DSP-6952 - Drug Profile 60 E-2508 - Drug Profile 61 EB-420 - Drug Profile 62 GSK-3179106 - Drug Profile 63 ibodutant - Drug Profile 64 linaclotide - Drug Profile 65 linaclotide DR1 - Drug Profile 73 linaclotide DR2 - Drug Profile 74 lovastatin - Drug Profile 75 LT-4006 - Drug Profile 79 LX-1033 - Drug Profile 80 ondansetron hydrochloride CR - Drug Profile 82 ORP-101 - Drug Profile 88 PBF-677 - Drug Profile 89 plecanatide - Drug Profile 90 PR-38 - Drug Profile 99 pregabalin - Drug Profile 100 relenopride hydrochloride - Drug Profile 105 rifamycin CR - Drug Profile 107 rifaximin - Drug Profile 110 RQ-00202730 - Drug Profile 114 RQ-00310941 - Drug Profile 115 Small Molecules to Inhibit 5-HT2B and 5-HT7 Receptors for IBS and Migraine - Drug Profile 116 solabegron hydrochloride - Drug Profile 117 tenapanor hydrochloride - Drug Profile 120 VB-210 - Drug Profile 125 Irritable Bowel Syndrome - Dormant Projects 126 Irritable Bowel Syndrome - Discontinued Products 129 Irritable Bowel Syndrome - Product Development Milestones 130 Featured News & Press Releases 130 Appendix 145 Methodology 145 Coverage 145 Secondary Research 145 Primary Research 145 Expert Panel Validation 145 Contact Us 145 Disclaimer 146
List of Tables
Number of Products under Development for Irritable Bowel Syndrome, H1 2017 Number of Products under Development by Companies, H1 2017 Number of Products under Development by Companies, H1 2017 (Contd..1), H1 2017 Number of Products under Development by Universities/Institutes, H1 2017 Products under Development by Companies, H1 2017 Products under Development by Companies, H1 2017 (Contd..1), H1 2017 Products under Development by Universities/Institutes, H1 2017 Number of Products by Stage and Target, H1 2017 Number of Products by Stage and Target, H1 2017 (Contd..1), H1 2017 Number of Products by Stage and Mechanism of Action, H1 2017 Number of Products by Stage and Mechanism of Action, H1 2017 (Contd..1), H1 2017 Number of Products by Stage and Route of Administration, H1 2017 Number of Products by Stage and Molecule Type, H1 2017 Irritable Bowel Syndrome - Pipeline by 4D Pharma PLC, H1 2017 Irritable Bowel Syndrome - Pipeline by A. Menarini Industrie Farmaceutiche Riunite Srl, H1 2017 Irritable Bowel Syndrome - Pipeline by Alfa Wassermann SpA, H1 2017 Irritable Bowel Syndrome - Pipeline by Allergan Plc, H1 2017 Irritable Bowel Syndrome - Pipeline by Ardelyx Inc, H1 2017 Irritable Bowel Syndrome - Pipeline by Astellas Pharma Inc, H1 2017 Irritable Bowel Syndrome - Pipeline by CJ HealthCare Corp, H1 2017 Irritable Bowel Syndrome - Pipeline by ConSynance Therapeutics Inc, H1 2017 Irritable Bowel Syndrome - Pipeline by Cosmo Pharmaceuticals NV, H1 2017 Irritable Bowel Syndrome - Pipeline by Dong-A ST Co., Ltd., H1 2017 Irritable Bowel Syndrome - Pipeline by Eisai Co Ltd, H1 2017 Irritable Bowel Syndrome - Pipeline by Enterome Bioscience SA, H1 2017 Irritable Bowel Syndrome - Pipeline by GlaxoSmithKline Plc, H1 2017 Irritable Bowel Syndrome - Pipeline by Innovative Med Concepts LLC, H1 2017 Irritable Bowel Syndrome - Pipeline by Ironwood Pharmaceuticals Inc, H1 2017 Irritable Bowel Syndrome - Pipeline by Kissei Pharmaceutical Co Ltd, H1 2017 Irritable Bowel Syndrome - Pipeline by Lexicon Pharmaceuticals Inc, H1 2017 Irritable Bowel Syndrome - Pipeline by Napo Pharmaceuticals Inc, H1 2017 Irritable Bowel Syndrome - Pipeline by Pfizer Inc, H1 2017 Irritable Bowel Syndrome - Pipeline by RaQualia Pharma Inc, H1 2017 Irritable Bowel Syndrome - Pipeline by RedHill Biopharma Ltd, H1 2017 Irritable Bowel Syndrome - Pipeline by SK Biopharmaceuticals Co Ltd, H1 2017 Irritable Bowel Syndrome - Pipeline by Sumitomo Dainippon Pharma Co Ltd, H1 2017 Irritable Bowel Syndrome - Pipeline by Synergy Pharmaceuticals Inc, H1 2017 Irritable Bowel Syndrome - Pipeline by Synthetic Biologics Inc, H1 2017 Irritable Bowel Syndrome - Pipeline by Vitality Biopharma Inc, H1 2017 Irritable Bowel Syndrome - Dormant Projects, H1 2017 Irritable Bowel Syndrome - Dormant Projects, H1 2017 (Contd..1), H1 2017 Irritable Bowel Syndrome - Dormant Projects, H1 2017 (Contd..2), H1 2017 Irritable Bowel Syndrome - Discontinued Products, H1 2017
Speak to the report author to design an exclusive study to serve your research needs.
Your personal and confidential information is safe and secure.
